以最新收盘价计算，A股平均股价为13.29元，其中股价超过100元的有136只，相比上一个交易日增加3 只。 百元股作为判定市场热度的信号之一，历来受到投资者关注。证券时报·数据宝统计显示，截至9月10日 收盘，沪指报收3812.22点，上涨0.13%，A股平均股价为13.29元，个股股价分布看，股价超过100元的 有136只，股价在50元至100元的有444只，股价在30元至50元的有777只。 股价超百元个股中，收盘价最高的是贵州茅台，今日报收1522.01元，上涨1.13%，其次是寒武纪、吉比 特等，最新收盘价分别为1273.00元、478.30元。 市场表现方面，收盘股价超百元股中，今日平均上涨0.91%，跑赢沪指0.78个百分点。今日上涨的有79 只，涨停的有思泉新材、淳中科技等，下跌的有56只，跌幅居前的有海博思创、安博通等。 追溯发现，最新百元股近一个月平均上涨21.88%，其间沪指上涨4.87%，涨幅居前的有开普云、海博思 创、浙海德曼等，涨幅分别为102.42%、88.03%、86.96%，今年以来平均涨幅为81.39%，强于沪指 67.66%，累计涨幅居前的有胜宏科技、思泉新材、浙海德曼等 ...

Core Insights - The report released by Wisdom芽 highlights the increasing presence of Chinese companies in the global innovation landscape, with 11 Chinese firms making it to the "2025 Global Innovation Leaders TOP 100" list [1] - Chinese companies are leading in technology exports, with PCT patent submissions accounting for approximately 47% of the total as of July this year [1] - The report identifies information technology and semiconductors as the dominant sectors, with 17 and 16 companies respectively in the Chinese innovation leaders list [1] - The Beijing-Tianjin-Hebei region shows active R&D, while the Guangdong-Hong Kong-Macau area is recognized for its high-quality technology influence [1] - The global innovation leader landscape is undergoing generational shifts, with new companies driving a quarter of global technological innovation [1] - The semiconductor sector has seen a significant increase, with 13 leading companies entering the global innovation leaders list [1] Company Highlights - The "2025 China Innovation Leaders TOP 100" includes major firms such as Huawei, ZTE, SMIC, Alibaba, BYD, and Mindray, representing the strongest technological capabilities in China [2] - New entrants to the list this year include BGI Genomics, JD.com, Kuaishou Technology, and others, indicating a dynamic shift in the innovation landscape [3] - The report emphasizes the role of these companies as pioneers in advancing China's strategy for technological self-reliance [2]

Investment Rating - The report maintains a "Buy" rating for the company [3][6]. Core Insights - The company is approaching a domestic turning point while maintaining steady growth overseas. The first half of 2025 saw a revenue of 16.74 billion yuan, a year-on-year decrease of 18.4%, and a net profit attributable to the parent company of 5.07 billion yuan, down 33.0% year-on-year. Domestic revenue was 8.41 billion yuan, down 33.4% year-on-year, attributed to extended income recognition cycles from public tenders. However, the third quarter is expected to show significant improvement as tender activities gradually recover [9]. - The company’s international business achieved revenue of 8.33 billion yuan, up 5.4% year-on-year, benefiting from the continuous breakthrough in high-end customer segments and the gradual improvement of local platforms [9]. - The company has maintained high R&D investment, with 1.78 billion yuan in the first half of 2025, accounting for 10.6% of revenue. It has established a digital medical ecosystem and launched several new products in the in vitro diagnostics and medical imaging sectors [9]. Financial Forecast and Investment Recommendations - Based on the mid-2025 report, the company’s earnings per share (EPS) for 2025-2027 are projected to be 9.64, 10.81, and 12.40 yuan respectively, down from previous estimates of 10.63, 12.13, and 13.77 yuan. The target price is set at 308.48 yuan, based on a 32 times price-to-earnings (PE) ratio for 2025 [3][6]. - The company’s revenue is expected to grow from 34.93 billion yuan in 2023 to 48.98 billion yuan in 2027, with a compound annual growth rate (CAGR) of 14.3% [5][11]. Key Financial Metrics - The company’s gross margin is projected to be 63.3% in 2025, with a net profit margin of 30.2% [5][11]. - The return on equity (ROE) is expected to decline from 35.6% in 2023 to 29.3% in 2025, reflecting the impact of increased competition and market conditions [5][11]. Market Performance - As of September 9, 2025, the company’s stock price was 241 yuan, with a 52-week high of 344.56 yuan and a low of 203.88 yuan [6].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][41]. Core Views - The pharmaceutical sector has shown resilience, outperforming the overall market with a 1.40% increase, while the total A-share market declined by 1.17% [1][32]. - ANGPTL3 has gained significant interest from multinational pharmaceutical companies (MNCs) due to its unique mechanism of action, which is non-LDLR dependent, making it effective in patients with LDLR deficiencies [3][30]. - The report highlights the diverse drug forms targeting ANGPTL3, with MNCs like Novartis, Lilly, Amgen, and AstraZeneca actively investing in this area, indicating a potential for multi-target and multi-drug combinations in the future [3][16]. Summary by Sections Market Performance - The overall A-share market fell by 1.17%, with the Shanghai and Shenzhen 300 index down by 0.81%. The biotechnology sector, however, rose by 1.40%, indicating strong performance relative to the broader market [1][32]. - Specific segments within the pharmaceutical sector showed varied performance, with chemical pharmaceuticals up by 3.92% and medical services up by 1.69%, while medical devices and traditional Chinese medicine saw declines [1][32]. ANGPTL3 Developments - A collaboration between Argo Biopharma and Novartis was announced, focusing on RNA drugs for cardiovascular diseases, with a total potential payment of $5.2 billion, including a $160 million upfront payment [2][11]. - ANGPTL3's mechanism allows for significant reductions in LDL-C levels in patients with HoFH, outperforming traditional treatments like PCSK9 inhibitors [3][31]. Company Earnings Forecasts and Ratings - Key companies in the sector, such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, have been rated as "Outperform" with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion yuan [4][41]. - The report provides detailed earnings forecasts for various companies, indicating a positive outlook for the sector as a whole [4][41]. Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector stands at 40.75x, significantly higher than the overall A-share market's 19.80x [37][38]. - Sub-sectors such as chemical pharmaceuticals and biological products have even higher valuations, indicating strong investor interest and growth potential [37][38]. Recommended Stocks - The report recommends several companies, including Mindray Medical for its strong market position and international expansion, WuXi AppTec for its comprehensive drug development services, and Aier Eye Hospital for its leading position in the eye care sector [41][42].

Core Viewpoint - The company has identified three high-potential business areas: minimally invasive surgery, animal healthcare, and cardiovascular, which collectively generated over 4 billion yuan in revenue last year, accounting for more than 10% of total revenue, with growth rates exceeding 25% [1][2][3] Minimally Invasive Surgery - The minimally invasive surgery segment has achieved over 10% market share within a few years, ranking just behind two imported brands, with a significant market potential exceeding 20 billion yuan [1] - The core products, ultrasonic scalpel and endoscopic stapler, have a combined market capacity exceeding 11 billion yuan, with a high concentration of market share among two imported brands [1] - The company is actively participating in multiple procurement projects and is investing in building a professional sales team to accelerate business growth [1] Animal Healthcare - The animal healthcare sector has seen significant development due to increased R&D investment, now offering a complete digital solution and achieving over 80% of international revenue from high-end pet hospitals [2] - The company plans to enhance its product portfolio in animal healthcare based on successful technology accumulation from human products to further penetrate the overseas high-end pet hospital market [2] Cardiovascular - The company is collaborating with Huatai Medical to improve operational efficiency while maintaining Huatai's independence, with a focus on enhancing the three-dimensional electrophysiology system's core competencies [2] - The establishment of the electrophysiology division has been completed, and the company is leveraging its R&D capabilities to support Huatai in clinical applications for atrial fibrillation [2] Industry Outlook - Despite short-term challenges in the industry, the company is expected to return to a growth trajectory through rapid development of high-potential businesses, AI technology upgrades, and international strategies [3] - The company anticipates a turning point in the domestic market in the third quarter and aims to solidify its leading position in the global medical device sector [3]

Core Insights - The China Securities Index for the Guangdong-Hong Kong-Macao Greater Bay Area (931000) has shown a strong increase of 1.10% as of September 10, 2025, with notable gains in constituent stocks such as Shenghong Technology (300476) up by 13.24% and Industrial Fulian (601138) up by 10.00% [1] Performance Summary - The Greater Bay Area ETF (512970) has risen by 0.92%, with a latest price of 1.43 yuan, and has accumulated a 9.48% increase over the past month as of September 9, 2025 [1] - Over the past year, the Greater Bay Area ETF has seen a net value increase of 47.70%, with the highest single-month return recorded at 21.99% and the longest consecutive monthly gain lasting 4 months with a total increase of 26.18% [1] - The average monthly return during the rising months is 5.38%, and the ETF has outperformed its benchmark with an annualized excess return of 8.81% over the last three months [1] Liquidity and Trading Activity - The trading volume for the Greater Bay Area ETF was 3.68 million yuan with a turnover rate of 0.04% as of September 9, 2025, and the average daily trading volume over the past month was 748,200 yuan [1] Risk and Fee Structure - The Greater Bay Area ETF has a management fee rate of 0.15% and a custody fee rate of 0.05% [2] Tracking Accuracy - The tracking error for the Greater Bay Area ETF was 0.029% over the past month, indicating a close alignment with the underlying index [3] Top Holdings - As of August 29, 2025, the top ten weighted stocks in the index include China Ping An (601318), BYD (002594), and China Merchants Bank (600036), collectively accounting for 49.06% of the index [4]

8月27日晚间，迈瑞医疗发布2025年半年报。今年上半年，公司实现营业收入167.43亿元，同比减少18.45%；实现归 属于上市公司股东的净利润约为50.69亿元，同比减少32.96%，这也是迈瑞医疗上市以来首次中报业绩出现负增长。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入(元) | 16.743.003.854.00 | 20,530,596,799.00 | -18.45% | | 归属于上市公司股东的净利润(元) | 5.068.767.098.00 | 7.560,737,744.00 | -32.96% | | 归属于上市公司股东的扣除非经常性损 益的净利润(元) | 4.949.323,103.00 | 7,379,931,633.00 | -32.94% | | 经营活动产生的现金流量净额(元) | 3,922,092,201.00 | 8.495.794.956.00 | -53.83% | | 基本每股收益(元/股) | 4.1840 | 6.2446 | -33.00% | | 稀释每股收益(元/股) ...

交易信息汇总资金流向 9月9日主力资金净流入5106.22万元；游资资金净流出1.35亿元；散户资金净流入8358.52万元。 大宗交易 截至2025年9月9日收盘，迈瑞医疗(300760)报收于241.0元，下跌2.84%，换手率0.95%，成交量11.47万 手，成交额27.92亿元。 当日关注点 投资者： 半年报里23页第二行说：公司实现MT 8000 全实验室智能化流水线销售 13 套，但是在同页的 中部却又说：报告期内，MT 8000 全实验室智能化流水线新增订单 185 套，这前后相差近15倍，请问是 哪个数据有错。 董秘： 您好，谢谢关注。"公司实现MT 8000 全实验室智能化流水线销售13套"指的是报告期内MT 8000 在国际市场的销售数量，185套是报告期内MT 8000在国内市场的销售数量。谢谢。 投资者： 公司和宇树科技有合作么 董秘： 您好，公司目前不涉及问题中提到的合作，谢谢。 投资者： 公司技术与专利是否可拓展到非医疗领域？ 董秘： 您好，谢谢关注，公司主要从事医疗器械的研发、制造、营销及服务，始终以客户需求为导 向，致力于为全球医疗机构提供优质的产品、服务和解决方案。谢谢。 ...

证券时报•数据宝统计显示，迈瑞医疗今日收盘价为241.00元，下跌2.84%，日换手率为0.95%，成交额 为27.92亿元，全天主力资金净流入4619.13万元，近5日该股累计上涨0.08%，近5日资金合计净流入2.42 亿元。 （原标题：迈瑞医疗9月9日大宗交易成交2410.00万元） 迈瑞医疗9月9日大宗交易平台出现一笔成交，成交量10.00万股，成交金额2410.00万元，大宗交易成交 价为241.00元。该笔交易的买方营业部为华泰证券股份有限公司广州珠江西路证券营业部，卖方营业部 为华泰证券股份有限公司广州珠江西路证券营业部。 进一步统计，近3个月内该股累计发生34笔大宗交易，合计成交金额为11.45亿元。 两融数据显示，该股最新融资余额为29.43亿元，近5日增加7467.53万元，增幅为2.60%。（数据宝） 9月9日迈瑞医疗大宗交易一览 | 成交 | 成交金 | | 相对当 | | | | --- | --- | --- | --- | --- | --- | | 量 | 额 | 成交价 | 日 | | | | | | 格 | 收盘折 | 买方营业部 | 卖方营业部 | | （万 | （万 | ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Insights - The company's performance is in line with expectations, with a significant improvement anticipated in domestic performance in Q3 2025. The total revenue for the first half of 2025 was 16.743 billion yuan, with domestic revenue at 8.411 billion yuan, reflecting a year-on-year decline of 33.37%. This decline is attributed to the extended cycle from public bidding to revenue recognition, as the revenue corresponds to a significant drop in 2024's bidding. A recovery in hospital procurement activities is expected to lead to a performance turning point in Q3 2025 [2][13]. - The company has successfully penetrated high-end overseas markets, with overseas revenue reaching 8.332 billion yuan in the first half of 2025, a year-on-year increase of 5.39%. The overseas revenue now accounts for approximately 50% of total revenue, with significant growth in regions such as the CIS and Middle East Africa. The company plans to enhance its local production capabilities in 14 countries, with 11 already initiated, to meet overseas market demand [2][13]. - The company continues to strengthen its core competitive advantages across three main business areas. In the in-vitro diagnostics sector, revenue was 6.424 billion yuan, down 16.11% year-on-year, while overseas sales showed double-digit growth. In the medical imaging sector, revenue was 3.312 billion yuan, down 22.51% year-on-year, but is expected to recover as domestic bidding activities improve. The life information and support segment generated 5.479 billion yuan, down 31.59% year-on-year, with international revenue now constituting 67% of this segment [2][13]. Summary by Sections Financial Performance - In the first half of 2025, the company achieved total revenue of 16.743 billion yuan, a year-on-year decline of 18.45%, with a net profit of 5.069 billion yuan, down 32.96%. The second quarter alone saw revenue of 8.506 billion yuan, down 23.77%, and a net profit of 2.440 billion yuan, down 44.55% [6][13]. Future Outlook - The company is expected to see a recovery in domestic performance in Q3 2025, driven by a resurgence in hospital procurement activities and the rollout of medical equipment updates. The overseas market is also projected to accelerate in the second half of 2025, supported by ongoing breakthroughs with high-end clients [2][13]. Business Segments - The in-vitro diagnostics segment is focusing on new product launches, with eight new chemical luminescence reagent products introduced in the first half of 2025. The medical imaging segment is expected to stabilize and grow, while the life information and support segment is expanding its international presence [2][13]. Valuation - The projected net profits for the company from 2025 to 2027 are estimated at 11.5 billion, 13.4 billion, and 15.6 billion yuan respectively, with corresponding price-to-earnings ratios of 26, 22, and 19 times [13].